To evaluate long-term quality of life (QoL) and participant reported symptom burden in disease-free survivors who have undergone cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) at MD Anderson, with primary emphasis on overall (composite) QoL as measured by validated instruments.
Males and females; age ≥18 years at the time of enrollment
Underwent curative-intent CRS/HIPEC at MD Anderson for gastrointestinal malignancies, including colorectal cancers, appendiceal cancers, and peritoneal mesothelioma between March 1, 2016, and June 30, 2025
Had a complete cytoreduction with a completeness of cytoreduction score (CC) of 0 or 1
Currently alive and at least 6 months disease-free post-CRS/HIPEC, based on clinical documentation and follow-up imaging
1. Evidence of recurrent or active malignancy at time of chart review 2. Underwent CRS/HIPEC for non-malignant conditions (e.g., multicystic mesothelioma, well-differentiated papillary mesothelioma) 3. Underwent palliative-intent surgery or had an incomplete cytoreduction (CC-2 or CC-3) 4. Did not receive HIPEC (CRS only) 5. Received HIPEC on a clinical trial 6. Significant cognitive impairment limiting ability to provide informed consent or complete the survey 7. Non-English-speaking (due to lack of validated translations for study instruments) 8. No valid contact information or no access to electronic communication (e.g., participant portal or email)
UT MD Anderson Cancer Center
Cohort
Cross-sectional
Questionnaire and Physical Exam
Other interventionAll questionnaires will be complete remotely through REDCap
Quality of Life Questionnaire
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
